Hydromorphon G.L. (Hydromorphone Hydrochloride)

Hydromorphon G.L. is an opioid analgesic used to manage pain conditions across several clinical pathways.

• Moderate to severe pain: Provides strong analgesia for acute or chronic pain in adult patients.
• Acute postoperative pain: Reduces pain intensity following surgical procedures.
• Cancer pain: Controls persistent pain associated with malignant disease.

• Hydromorphone acts as a full agonist at the µ‑opioid receptors in the central nervous system. Binding to these receptors inhibits the release of nociceptive neurotransmitters, leading to decreased perception of pain and increased sedation. The drug also modulates descending pain pathways, contributing to its potent analgesic effect.

Hydromorphon G.L. may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: feeling of sickness or urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Dry mouth: reduced salivation leading to throat discomfort.
• Sweating: excessive perspiration without exertion.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Addiction or dependence: potential for misuse with prolonged exposure.
• Anaphylaxis: rare severe allergic reaction with rash, swelling, and airway compromise.
• Adrenal insufficiency: impaired cortisol production leading to fatigue and weakness.
• Seizures: rare occurrence of convulsive episodes.

Before prescribing Hydromorphon G.L., clinicians should consider several safety measures.

• Assess pain level and opioid tolerance: evaluate patient history before initiating therapy.
• Avoid use in patients with significant respiratory depression: monitor breathing closely.
• Use caution in renal or hepatic impairment: dose adjustment may be required.
• Concurrent CNS depressants: increased risk of sedation and respiratory depression.
• Pregnancy and lactation: weigh benefits against potential risks; limited data available.
• Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Hydromorphon G.L. can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid)

• Concomitant use with other opioids: additive respiratory depression.
• Benzodiazepines or barbiturates: increased sedation and respiratory risk.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect.
• Anticholinergic agents: may exacerbate constipation.